Kura Oncology, Inc.

KURA · Nasdaq · SIC 2834: Pharmaceutical Preparations
256
SEC Filings

Business Summary

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for patients with genetically defined cancers. Its lead product, KOMZIFTI (ziftomenib), received FDA approval for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The company is pursuing additional indications for ziftomenib, including frontline AML and combination therapies, and has a collaboration with Kyowa Kirin Co., Ltd. for global development.

Next Earnings

Q2 FY2026 — expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionKURAdiscussed_in_filing Blockchain & Crypto
topic_mentionKURAdiscussed_in_filing Healthcare & Bio
topic_mentionKURAdiscussed_in_filing Blockchain & Crypto
topic_mentionKURAdiscussed_in_filing Healthcare & Bio
topic_mentionKURAdiscussed_in_filing Blockchain & Crypto
topic_mentionKURAdiscussed_in_filing Healthcare & Bio
topic_mentionKURAdiscussed_in_filing Blockchain & Crypto
topic_mentionKURAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001193125-26-092567EDGAR96K words
2025-02-282024-12-310000950170-25-029975EDGAR—
2024-02-272023-12-310000950170-24-021094EDGAR—
2023-02-232022-12-310000950170-23-004107EDGAR—
2022-02-242021-12-310000950170-22-001967EDGAR—
2021-02-242020-12-310001564590-21-007822EDGAR—
2020-02-252019-12-310001564590-20-006391EDGAR—
2019-03-052018-12-310001564590-19-006263EDGAR—
2018-03-122017-12-310001564590-18-005293EDGAR—
2017-03-142016-12-310001564590-17-004291EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001193125-25-263589EDGAR58K words
2025-08-072025-06-300000950170-25-105051EDGAR—
2025-05-012025-03-310000950170-25-061848EDGAR—
2024-11-072024-09-300000950170-24-123363EDGAR—
2024-08-082024-06-300000950170-24-093997EDGAR—
2024-05-022024-03-310000950170-24-052136EDGAR—
2023-11-022023-09-300000950170-23-058173EDGAR—
2023-08-092023-06-300000950170-23-040556EDGAR—
2023-05-102023-03-310000950170-23-020526EDGAR—
2022-11-032022-09-300000950170-22-021605EDGAR—
2022-08-032022-06-300000950170-22-014251EDGAR—
2022-05-042022-03-310000950170-22-007404EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-050001193125-26-092465EDGAR4K words
2026-01-290001193125-26-029705EDGAR—
2026-01-120001193125-26-009649EDGAR—
2025-12-020001193125-25-304559EDGAR—
2025-11-130001193125-25-280255EDGAR—
2025-11-040001193125-25-263491EDGAR—
2025-10-240001193125-25-249348EDGAR—
2025-10-160001193125-25-241416EDGAR—
2025-08-070000950170-25-105024EDGAR—
2025-07-010001193125-25-153393EDGAR—

256 total filings indexed. 224 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology acute-myeloid-leukemia-(aml) genetically-defined-cancers

Company Identity

CIK0001422143
TickerKURA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d6887928fd9ce26a56242c004497d8cbe97e7ade9cbdf07f5a5141da1b46d9be
parent: e3ef0aafaf36812360d29d2767b0e66fbb62b81c181acb48800bbe85f7025d55
content hash: c7e9407d27c341035b7af4a055261296fa209f3f7552428c38847b1dd3862756
signed: 2026-04-13T04:45:56.967Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf